Premium
A Highly Soluble Matrix Metalloproteinase‐9 Inhibitor for Potential Treatment of Dry Eye Syndrome
Author(s) -
Mori Mattia,
De Lorenzo Emanuele,
Torre Eugenio,
Fragai Marco,
Nativi Cristina,
Luchinat Claudio,
Arcangeli Annarosa
Publication year - 2012
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2012.00896.x
Subject(s) - in vivo , matrix metalloproteinase , keratoconjunctivitis , keratoconjunctivitis sicca , in vitro , pharmacology , ophthalmology , pathogenesis , matrix (chemical analysis) , medicine , chemistry , dermatology , pathology , biochemistry , biology , microbiology and biotechnology , chromatography
Dry eye syndrome ( DES ) or keratoconjunctivitis sicca is an eye disease caused by the chronic lack of lubrication and moisture of the eye. The pathogenesis of DES involves the over‐expression and over‐activity of corneal Matrix Metalloproteinase 9 ( MMP ‐9). We propose herein a new, non‐symptomatic approach for the treatment of DES based on the inhibition of MMP ‐9 by a new highly soluble molecule, designed as PES _103 that has been shown to inhibit MMP ‐9 both in vitro and in vivo . The efficacy of PES _103 in vivo and the potential benefits of this treatment in restoring tear production were studied in this work using an animal model of reduced lacrimation. PES _103 did not show any significant corneal toxicity.